ERBB2 and breast cancer: For patients with HER2+ early breast cancer with pT1 without evidence of nodal disease (pN0), the standard of care adjuvant systemic treatment is paclitaxel + trastuzumab for 12 weeks followed by trastuzumab monotherapy for 9 months (strong recommendation).